Terms: = Brain cancer AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2 AND Treatment
171 results:
1. Predicting the prognosis of glioma patients with tert promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy.
Cao W; Lan J; Hu C; Kong J; Xiang L; Zhang Z; Sun Y; Zeng Z; Lei S
Aging (Albany NY); 2024 Mar; 16(6):5618-5633. PubMed ID: 38499392
[TBL] [Abstract] [Full Text] [Related]
2. Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib.
Cabezas-Camarero S; García-Barberán V; Pérez-Alfayate R; Gómez Del Pulgar ME; Cabrera-Martin MN; Casado-Fariñas I; Pérez-Segura P
Oncologist; 2024 May; 29(5):377-383. PubMed ID: 38438322
[TBL] [Abstract] [Full Text] [Related]
3. treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F
J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661
[TBL] [Abstract] [Full Text] [Related]
4. The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target?
Di Nunno V; Aprile M; Bartolini S; Gatto L; Tosoni A; Ranieri L; De Biase D; Asioli S; Franceschi E
Cells; 2023 Dec; 13(1):. PubMed ID: 38201248
[TBL] [Abstract] [Full Text] [Related]
5. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
Hadad S; Gupta R; Oberheim Bush NA; Taylor JW; Villanueva-Meyer JE; Young JS; Wu J; Ravindranathan A; Zhang Y; Warrier G; McCoy L; Shai A; Pekmezci M; Perry A; Bollen AW; Phillips JJ; Braunstein SE; Raleigh DR; Theodosopoulos P; Aghi MK; Chang EF; Hervey-Jumper SL; Costello JF; de Groot J; Butowski NA; Clarke JL; Chang SM; Berger MS; Molinaro AM; Solomon DA
Acta Neuropathol; 2023 Dec; 147(1):3. PubMed ID: 38079020
[TBL] [Abstract] [Full Text] [Related]
6. Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review.
Zúñiga D; Stumpf MAM; Monteiro ALS; Glezer A
J Endocrinol Invest; 2024 May; 47(5):1295-1303. PubMed ID: 37938428
[TBL] [Abstract] [Full Text] [Related]
7. Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial.
Cappelli L; Khan MM; Kayne A; Poiset S; Miller R; Ali A; Niazi M; Shi W; Alnahhas I
Chin Clin Oncol; 2023 Jun; 12(3):23. PubMed ID: 37417289
[TBL] [Abstract] [Full Text] [Related]
8. Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.
Benusiglio PR; Elder F; Touat M; Perrier A; Sanson M; Colas C; Guerrini-Rousseau L; Tran DT; Trabelsi N; Carpentier C; Marie Y; Adam C; Bernier M; Cazals-Hatem D; Mokhtari K; Tran S; Mathon B; Capelle L; Dhooge M; Idbaih A; Alentorn A; Houillier C; Dehais C; Hoang-Xuan K; Cuzzubbo S; Carpentier A; Duval A; Coulet F; Bielle F
JCO Precis Oncol; 2023 May; 7():e2200525. PubMed ID: 37262394
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic role and interaction of tert promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients.
Giunco S; Padovan M; Angelini C; Cavallin F; Cerretti G; Morello M; Caccese M; Rizzo B; d'Avella D; Puppa AD; Chioffi F; De Bonis P; Zagonel V; De Rossi A; Lombardi G
ESMO Open; 2023 Jun; 8(3):101570. PubMed ID: 37230028
[TBL] [Abstract] [Full Text] [Related]
10. Survival benefit of prophylactic cranial irradiation in limited-stage small-cell lung cancer in modern magnetic resonance imaging staging: a systematic review and meta-analysis.
Liu J; Shen B; Yang Y; Guo J; Ren W; Zhou Q; Mao J; Ye W; Wu D
Acta Oncol; 2023 Mar; 62(3):305-314. PubMed ID: 37010509
[TBL] [Abstract] [Full Text] [Related]
11. tert Immunohistochemistry as a Surrogate Marker for tert Promoter Mutations in Infiltrating Gliomas.
Dono A; Moosvi AM; Goli PS; Bellman AC; Aung PP; Esquenazi Y; Ballester LY
Appl Immunohistochem Mol Morphol; 2023 May-Jun 01; 31(5):288-294. PubMed ID: 36952585
[TBL] [Abstract] [Full Text] [Related]
12. Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations.
Sun A; Abdulkarim B; Blais N; Greenland J; Louie AV; Melosky B; Schellenberg D; Snow S; Liu G
Lung Cancer; 2023 May; 179():107166. PubMed ID: 36944282
[TBL] [Abstract] [Full Text] [Related]
13. Deep Learning Radiomics for the Assessment of Telomerase Reverse Transcriptase Promoter Mutation Status in Patients With Glioblastoma Using Multiparametric MRI.
Zhang H; Zhang H; Zhang Y; Zhou B; Wu L; Lei Y; Huang B
J Magn Reson Imaging; 2023 Nov; 58(5):1441-1451. PubMed ID: 36896953
[TBL] [Abstract] [Full Text] [Related]
14. Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1.
Romo CG; Piotrowski AF; Campian JL; Diarte J; Rodriguez FJ; Bale TA; Dahiya S; Gutmann DH; Lucas CG; Prichett L; Mellinghoff I; Blakeley JO
Neuro Oncol; 2023 Aug; 25(8):1474-1486. PubMed ID: 36840626
[TBL] [Abstract] [Full Text] [Related]
15. Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation.
Orzan F; De Bacco F; Lazzarini E; Crisafulli G; Gasparini A; Dipasquale A; Barault L; Macagno M; Persico P; Pessina F; Bono B; Giordano L; Zeppa P; Melcarne A; Cassoni P; Garbossa D; Santoro A; Comoglio PM; Indraccolo S; Simonelli M; Boccaccio C
Clin Cancer Res; 2023 Apr; 29(7):1252-1266. PubMed ID: 36648487
[TBL] [Abstract] [Full Text] [Related]
16. Imaging features of localized IDH wild-type histologically diffuse astrocytomas: a single-institution case series.
Kibe Y; Motomura K; Ohka F; Aoki K; Shimizu H; Yamaguchi J; Nishikawa T; Saito R
Sci Rep; 2023 Jan; 13(1):23. PubMed ID: 36646712
[TBL] [Abstract] [Full Text] [Related]
17. Synthesis and biological evaluation of tert-butyl ester and ethyl ester prodrugs of L-γ-methyleneglutamic acid amides for cancer.
Khan MIH; Mahdi F; Penfornis P; Akins NS; Hossain MI; Kim SJ; Sulochana SP; Adam AT; Tran TD; Tan C; Paolo Claudio P; Paris JJ; Le HV
Bioorg Med Chem; 2023 Jan; 78():117137. PubMed ID: 36603398
[TBL] [Abstract] [Full Text] [Related]
18. Australian genome-wide association study confirms higher female risk for adult glioma associated with variants in the region of CCDC26.
Alpen K; Vajdic CM; MacInnis RJ; Milne RL; Koh ES; Hovey E; Harrup R; Bruinsma F; Nguyen TL; Li S; Joseph D; Benke G; Dugué PA; Southey MC; Giles GG; Rosenthal M; Drummond KJ; Nowak AK; Hopper JL; Kapuscinski M; Makalic E
Neuro Oncol; 2023 Jul; 25(7):1355-1365. PubMed ID: 36541697
[TBL] [Abstract] [Full Text] [Related]
19. The Telomerase Connection of the brain and Its Implications for Neurodegenerative Diseases.
Saretzki G
Stem Cells; 2023 Mar; 41(3):233-241. PubMed ID: 36330760
[TBL] [Abstract] [Full Text] [Related]
20. Role of tert mutation for treatment prognosis in patients with IDH-negative anaplastic astrocytoma.
Belyaev AY; Kobyakov GL; Shmakov PN; Telysheva EN; Strunina YV; Usachev DY
Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(5):21-27. PubMed ID: 36252190
[TBL] [Abstract] [Full Text] [Related]
[Next]
